The abstract is read at the publisher; the summary is JClub's.
Colivin, an orally available KM-001 derivative, binds the TRPV3 vanilloid pocket to stabilize a non-conducting conformation and suppresses DSS-induced ulcerative colitis in wild-type mice.
- Why it matters: TRPV3’s intestinal function is not well defined, and existing TRPV3 inhibition approaches are limited by poor metabolic stability, leaving a gap for effective oral therapy in ulcerative colitis.
- What they did: The study compared Colivin with KM-001 for TRPV3-blocking activity and improved metabolic stability/oral bioavailability, then used cryo-EM and site-directed mutagenesis to map binding and conformational stabilization.
- The result: In mice, oral Colivin suppressed DSS-induced UC in wild-type but not Trpv3-deficient animals, supporting TRPV3 inhibition as a therapeutic strategy and clarifying the inhibition mechanism for inhibitor design.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.